source
- GSK receives FDA approval for hepatitis B therapy that expands functional cure ratesGSK announced that the U.S. Food and Drug Administration has granted approval for its hepatitis B drug. The agency said the treatment can achieve functional cures in a larger proportion of patient…
- Roivant reports Lisraya beats placebo in Phase 3 trials for non-infectious uveitisRoivant and its spinout Priovant announced that Lisraya, an immune-modifying oral drug, showed statistically significant benefit over placebo in two Phase 3 trials for non-infectious uveitis. The…